N4 virion single-stranded DNA dependent RNA polymerase
View Patent ↗A histidine-tagged, deletion mutant of bacteriophage N4-coded, virion RNA polymerase (mini-vRNAP) which is active has been developed. The his-tagged mini-vRNAP has been cloned under the control of the pBAD promoter, is stable and is purified in a single step yielding large amounts (10 mg/liter of E. coli expressing cells). This RNA polymerase uses single-stranded DNA containing 17 bases (the promoter) upstream of the transcribed regions as a template. In the presence of E. coli SSB protein, it transcribes this template efficiently, providing a unique system to synthesize RNAs of the desired sequence using single-stranded DNA templates. The enzyme incorporates derivatized nucleoside triphosphates with high efficiency. A mutant of mini-vRNAP has been generated that incorporates deoxynucleoside triphosphates. In addition, the inventors have developed an in vivo system to express RNAs and proteins under mini vRNA polymerase promoter control.
1. An isolated nucleic acid comprising a region encoding a polypeptide having an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:15.
2. The nucleic acid of claim 1 , wherein said nucleic acid comprises the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:14.
3. The nucleic acid of claim 1 , wherein said nucleic acid is operatively linked to a promoter.
4. The nucleic acid of claim 3 , wherein said promoter is an N4 vRNAP promoter set forth in SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:27, SEQ ID NO:28 or SEQ ID NO:29.
5. The nucleic acid of claim 3 , wherein said promoter is a P2 sequence set forth in SEQ ID NO:16 or SEQ ID NO:28.
6. An isolated recombinant host cell comprising a DNA segment comprising a DNA segment comprising the nucleic acid sequence of claim 1 .
7. The recombinant host cell of claim 6 , wherein said DNA segment is a single-stranded DNA segment.
8. The recombinant host cell of claim 6 , wherein said DNA segment is a double-stranded DNA segment.
9. The recombinant host cell of claim 6 , wherein said DNA segment encodes a polypeptide having an amino acid sequence set forth in SEQ ID NO:4.
10. The recombinant host cell of claim 6 , wherein said DNA segment encodes a polypeptide having an amino acid sequence set forth in SEQ ID NO:6.
11. The recombinant host cell of claim 6 , wherein said cell is an E. coli cell.
12. A recombinant vector comprising a DNA segment encoding a N4 virion RNA polymerase polypeptide under the control of a promoter, wherein the DNA segment comprises the nucleic acid sequence of claim 1 .
13. An isolated polynucleotide comprising a sequence identical or completely complementary to the full length of SEQ ID NO:1.
14. An isolated polynucleotide comprising a sequence identical or completely complementary to the full length of SEQ ID NO:3.
15. The nucleic acid of claim 1 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.
16. An isolated nucleic acid encoding the polypeptide of SEQ ID NO:4 wherein said polypeptide has a mutation at position Y678.
17. A method of making a full-length N4 vRNAP or mini-vRNAP comprising:
(a) expressing an isolated nucleic acid sequence encoding vRNAP, wherein said vRNAP has the amino sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 or, SEQ ID NO:15; and
(b) purifying said vRNAP.
18. The method of claim 17 , wherein said expressing occurs in a bacteria, yeast, CHO, Cos, HeLa, NIH3T3, Jurkat, 293, Saos, or PC12 host cell.
19. The method of claim 17 , further comprising using a promoter appropriate for expression in the host cell line being used.
20. The method of claim 19 , wherein said promoter is pBAD.
21. The method of claim 19 , wherein said promoter is a promoter recognized by T7 RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase.
22. The method of claim 19 , wherein said promoter is a promoter recognized by T7-like RNA polymerase.
23. The method of claim 17 , wherein said vRNAP has a specific recombinant sequence for use in purification.
24. The method of claim 23 , wherein said vRNAP has at least one histidine, FLAG, hemaglutinin or c-myc tag.
25. The method of claim 23 , wherein said vRNAP has at least one histidine tag.
26. The method of claim 24 , wherein said purifying occurs in one step.
27. The method of claim 17 , wherein said vRNAP does not have a tag.